D. Boral Capital Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Friday,Benzinga reports. They presently have a $9.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Wednesday, March 26th.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.78 on Friday. The company has a market cap of $93.17 million, a P/E ratio of -0.40 and a beta of 0.40. The firm’s fifty day moving average is $0.63 and its two-hundred day moving average is $0.75. Invivyd has a 52-week low of $0.35 and a 52-week high of $2.74.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The business had revenue of $11.30 million for the quarter, compared to the consensus estimate of $34.45 million. As a group, analysts forecast that Invivyd will post -1.64 EPS for the current fiscal year.

Institutional Trading of Invivyd

A number of large investors have recently made changes to their positions in IVVD. Barclays PLC grew its holdings in Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after purchasing an additional 9,207 shares during the last quarter. Invesco Ltd. grew its holdings in Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares during the last quarter. Jane Street Group LLC grew its holdings in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after purchasing an additional 87,358 shares during the last quarter. Nuveen LLC bought a new position in Invivyd during the 1st quarter valued at about $65,000. Finally, XTX Topco Ltd bought a new position in Invivyd during the 1st quarter valued at about $66,000. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.